Berlin, Germany, June 15, 2012 / B3C newswire / – GLYCOTOPE is due to successfully complete Phase I of its glycooptimized therapeutic antibody PankoMab™ and will move the compound to Phase II of clinical development in ovarian cancer with further indications planned to follow.
PankoMab-GEX™ is based on Glycotope’s unique and proprietary GlycoBodies™ technology and recognizes carbohydrate based tumor epitopes. This humanized and tumor-specific antibody is particularly suitable for e.g. ovarian and lung cancers and binds to over 90% of cases in several solid cancer indications. PankoMab-GEX™ expresses a series of potent anti-tumor modes of action strongly enhanced by glycooptimization through Glycotope’s GlycoExpress™ platform. This allows significantly improved treatment outcome compared to non-glycooptimized biotherapeutics. Preliminary results of the Phase I studies of PankoMab™ show very good tolerability, no significant toxicity and strong signals for high anti-tumor activity and specificity. “We are very excited about PankoMab-GEX™’s clinical potential” says Dr. Steffen Goletz, CEO, CSO and Founder of Glycotope. “The data show long-term anti-tumor efficacy including even complete response in patients progressive upon treatment start. This will be further investigated in Phase II studies.”
The global oncology market value is expected to reach USD 76.7 billion by 2014, reflecting the high medical need and opportunity in this area. In 2011 the ovarian cancer therapeutics market was worth USD 737 million in key countries with a projected value of USD 2.4 billion by 2020. With its three innovative oncological antibody lead compounds, PankoMab-GEX™, CetuGEX™ and TrasGEX™, all showing promising clinical data (to be presented soon) pointing towards significant therapeutic benefits in multiple oncology indication, Glycotope has the potential to play a prominent role in the future oncology market.
“Glycotope is very well positioned with a strong IP-base and its ongoing antibody and non-antibody programs. To date, we have clinical proof-of-concept for our technologies and we have so far no failure in clinical development” states Dr. Steffen Goletz. “We continue to deliver substantial value and with our promising preliminary results for PankoMab-GEX™, we are currently looking for a strong partner for advanced clinical development of this compound and to jointly investigate additional indications.”
GLYCOTOPE, founded in 2001 in Berlin, focuses on the development of innovative antibodies for the treatment of various cancer types, targeting glycostructures on cell surfaces. In addition, Glycotope develops so-called BioBetters, recombinant biopharmaceuticals with optimized and fully human sugar structures (via glycolysation), leading to improved efficacy, bioavailability, immunogenicity and correspondingly improved patient outcome. The company’s technologies will also enable a broadening of eligible patient populations and indications as well as improved cost-effectiveness. Glycotope currently has four products in clinical development stage. The company’s additional pipeline includes preclinical proteins for various indications.
Together with Glycotope-Biotechnology in Heidelberg, Glycotope evolved into a leading integrated glycobiology company, covering all phases in preclinical and clinical drug development and GMP production. With more than 150 employees and a strong and broad IP-platform, Glycotope has grown to one of the largest Biotech companies in Germany.
Dr. Franzpeter Bracht, CFO & CBO
Phone: +49-(0)30 94 89-2600
Fax: +49-(0)30 94 89-2609